EP2304033 - FUNCTIONALIZED POLYPEPTIDES [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 14.07.2017 Database last updated on 09.09.2024 | Most recent event Tooltip | 06.03.2020 | Lapse of the patent in a contracting state New state(s): TR | published on 08.04.2020 [2020/15] | Applicant(s) | For all designated states ESBATech, an Alcon Biomedical Research Unit LLC Wagistrasse 21 8952 Schlieren / CH | [2016/36] |
Former [2011/14] | For all designated states ESBATech, an Alcon Biomedical Research Unit LLC Wagistrasse 21 8952 Schlieren / CH | Inventor(s) | 01 /
URECH, David Widmen 8 8634 Hombrechtikon / CH | [2011/14] | Representative(s) | Grünecker Patent- und Rechtsanwälte PartG mbB Leopoldstraße 4 80802 München / DE | [2016/36] |
Former [2012/03] | Grünecker, Kinkeldey, Stockmair & Schwanhäusser Anwaltssozietät Leopoldstrasse 4 80802 München / DE | ||
Former [2011/14] | Molitor, Julia, et al c/o E.Blum & Co.AG Vorderberg 11 8044 Zürich / CH | Application number, filing date | 09775731.4 | 30.06.2009 | [2011/14] | WO2009CH00225 | Priority number, date | US20080076775P | 30.06.2008 Original published format: US 76775 P | [2011/14] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2010006454 | Date: | 21.01.2010 | Language: | EN | [2010/03] | Type: | A2 Application without search report | No.: | EP2304033 | Date: | 06.04.2011 | Language: | EN | The application published by WIPO in one of the EPO official languages on 21.01.2010 takes the place of the publication of the European patent application. | [2011/14] | Type: | B1 Patent specification | No.: | EP2304033 | Date: | 07.09.2016 | Language: | EN | [2016/36] | Search report(s) | International search report - published on: | EP | 25.03.2010 | Classification | IPC: | C12N15/62, C07K16/00, C07K16/22, C07K16/24, A61K47/48, C12N15/10 | [2016/20] | CPC: |
C12N15/1037 (EP,KR,US);
A61K47/60 (EP,KR,US);
A61K47/65 (EP,KR,US);
A61P31/00 (EP);
A61P37/00 (EP);
C07K16/00 (EP,KR,US);
C07K16/241 (EP,KR,US);
C12N15/1062 (EP,KR,US);
C07K2317/40 (US);
|
Former IPC [2011/14] | C12N15/62, C07K16/00, C07K16/22, C07K16/24, A61K47/48 | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR [2016/36] |
Former [2011/14] | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR | Title | German: | FUNKTIONALISIERTE POLYPEPTIDE | [2011/14] | English: | FUNCTIONALIZED POLYPEPTIDES | [2011/14] | French: | POLYPEPTIDES FONCTIONNALISÉS | [2011/14] | Entry into regional phase | 14.01.2011 | National basic fee paid | 14.01.2011 | Designation fee(s) paid | 14.01.2011 | Examination fee paid | Examination procedure | 14.01.2011 | Examination requested [2011/14] | 21.02.2011 | Amendment by applicant (claims and/or description) | 13.06.2012 | Despatch of a communication from the examining division (Time limit: M06) | 21.11.2012 | Reply to a communication from the examining division | 01.11.2013 | Despatch of a communication from the examining division (Time limit: M04) | 04.11.2013 | Despatch of a communication from the examining division (Time limit: M04) | 10.02.2014 | Reply to a communication from the examining division | 04.02.2015 | Despatch of a communication from the examining division (Time limit: M04) | 15.06.2015 | Reply to a communication from the examining division | 24.05.2016 | Communication of intention to grant the patent | 27.07.2016 | Fee for grant paid | 27.07.2016 | Fee for publishing/printing paid | 27.07.2016 | Receipt of the translation of the claim(s) | Divisional application(s) | EP16187295.7 / EP3130603 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 13.06.2012 | Opposition(s) | 08.06.2017 | No opposition filed within time limit [2017/33] | Fees paid | Renewal fee | 27.06.2011 | Renewal fee patent year 03 | 31.03.2012 | Renewal fee patent year 04 | 10.06.2013 | Renewal fee patent year 05 | 31.03.2014 | Renewal fee patent year 06 | 10.06.2015 | Renewal fee patent year 07 | 10.06.2016 | Renewal fee patent year 08 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Licence(s) | ID: | 01 01/exclusive | For: | AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR | Licencee: | Cell Medica Switzerland AG Wagistrasse 27 8952 Schlieren / CH | Date: | 03.07.2013 | [2016/43] |
Former [2013/36] | ID: | 01 01/exclusive | |
For: | AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR | ||
Licencee: | Delenex Therapeutics AG Wagistrasse 27 8952 Schlieren / CH | ||
Date: | 03.07.2013 | ||
[2016/43] | Lapses during opposition Tooltip | HU | 30.06.2009 | AT | 07.09.2016 | BE | 07.09.2016 | CY | 07.09.2016 | CZ | 07.09.2016 | DK | 07.09.2016 | EE | 07.09.2016 | ES | 07.09.2016 | FI | 07.09.2016 | HR | 07.09.2016 | IT | 07.09.2016 | LT | 07.09.2016 | LV | 07.09.2016 | MC | 07.09.2016 | MK | 07.09.2016 | NL | 07.09.2016 | PL | 07.09.2016 | RO | 07.09.2016 | SE | 07.09.2016 | SI | 07.09.2016 | SK | 07.09.2016 | TR | 07.09.2016 | BG | 07.12.2016 | NO | 07.12.2016 | GR | 08.12.2016 | IS | 07.01.2017 | PT | 09.01.2017 | [2020/15] |
Former [2019/51] | HU | 30.06.2009 | |
AT | 07.09.2016 | ||
BE | 07.09.2016 | ||
CY | 07.09.2016 | ||
CZ | 07.09.2016 | ||
DK | 07.09.2016 | ||
EE | 07.09.2016 | ||
ES | 07.09.2016 | ||
FI | 07.09.2016 | ||
HR | 07.09.2016 | ||
IT | 07.09.2016 | ||
LT | 07.09.2016 | ||
LV | 07.09.2016 | ||
MC | 07.09.2016 | ||
MK | 07.09.2016 | ||
NL | 07.09.2016 | ||
PL | 07.09.2016 | ||
RO | 07.09.2016 | ||
SE | 07.09.2016 | ||
SI | 07.09.2016 | ||
SK | 07.09.2016 | ||
BG | 07.12.2016 | ||
NO | 07.12.2016 | ||
GR | 08.12.2016 | ||
IS | 07.01.2017 | ||
PT | 09.01.2017 | ||
Former [2019/46] | HU | 30.06.2009 | |
AT | 07.09.2016 | ||
BE | 07.09.2016 | ||
CY | 07.09.2016 | ||
CZ | 07.09.2016 | ||
DK | 07.09.2016 | ||
EE | 07.09.2016 | ||
ES | 07.09.2016 | ||
FI | 07.09.2016 | ||
HR | 07.09.2016 | ||
IT | 07.09.2016 | ||
LT | 07.09.2016 | ||
LV | 07.09.2016 | ||
MC | 07.09.2016 | ||
NL | 07.09.2016 | ||
PL | 07.09.2016 | ||
RO | 07.09.2016 | ||
SE | 07.09.2016 | ||
SI | 07.09.2016 | ||
SK | 07.09.2016 | ||
BG | 07.12.2016 | ||
NO | 07.12.2016 | ||
GR | 08.12.2016 | ||
IS | 07.01.2017 | ||
PT | 09.01.2017 | ||
Former [2019/31] | HU | 30.06.2009 | |
AT | 07.09.2016 | ||
BE | 07.09.2016 | ||
CZ | 07.09.2016 | ||
DK | 07.09.2016 | ||
EE | 07.09.2016 | ||
ES | 07.09.2016 | ||
FI | 07.09.2016 | ||
HR | 07.09.2016 | ||
IT | 07.09.2016 | ||
LT | 07.09.2016 | ||
LV | 07.09.2016 | ||
MC | 07.09.2016 | ||
NL | 07.09.2016 | ||
PL | 07.09.2016 | ||
RO | 07.09.2016 | ||
SE | 07.09.2016 | ||
SI | 07.09.2016 | ||
SK | 07.09.2016 | ||
BG | 07.12.2016 | ||
NO | 07.12.2016 | ||
GR | 08.12.2016 | ||
IS | 07.01.2017 | ||
PT | 09.01.2017 | ||
Former [2018/11] | AT | 07.09.2016 | |
BE | 07.09.2016 | ||
CZ | 07.09.2016 | ||
DK | 07.09.2016 | ||
EE | 07.09.2016 | ||
ES | 07.09.2016 | ||
FI | 07.09.2016 | ||
HR | 07.09.2016 | ||
IT | 07.09.2016 | ||
LT | 07.09.2016 | ||
LV | 07.09.2016 | ||
MC | 07.09.2016 | ||
NL | 07.09.2016 | ||
PL | 07.09.2016 | ||
RO | 07.09.2016 | ||
SE | 07.09.2016 | ||
SI | 07.09.2016 | ||
SK | 07.09.2016 | ||
BG | 07.12.2016 | ||
NO | 07.12.2016 | ||
GR | 08.12.2016 | ||
IS | 07.01.2017 | ||
PT | 09.01.2017 | ||
Former [2017/37] | AT | 07.09.2016 | |
BE | 07.09.2016 | ||
CZ | 07.09.2016 | ||
DK | 07.09.2016 | ||
EE | 07.09.2016 | ||
ES | 07.09.2016 | ||
FI | 07.09.2016 | ||
HR | 07.09.2016 | ||
IT | 07.09.2016 | ||
LT | 07.09.2016 | ||
LV | 07.09.2016 | ||
NL | 07.09.2016 | ||
PL | 07.09.2016 | ||
RO | 07.09.2016 | ||
SE | 07.09.2016 | ||
SI | 07.09.2016 | ||
SK | 07.09.2016 | ||
BG | 07.12.2016 | ||
NO | 07.12.2016 | ||
GR | 08.12.2016 | ||
IS | 07.01.2017 | ||
PT | 09.01.2017 | ||
Former [2017/34] | AT | 07.09.2016 | |
BE | 07.09.2016 | ||
CZ | 07.09.2016 | ||
DK | 07.09.2016 | ||
EE | 07.09.2016 | ||
ES | 07.09.2016 | ||
FI | 07.09.2016 | ||
HR | 07.09.2016 | ||
IT | 07.09.2016 | ||
LT | 07.09.2016 | ||
LV | 07.09.2016 | ||
NL | 07.09.2016 | ||
PL | 07.09.2016 | ||
RO | 07.09.2016 | ||
SE | 07.09.2016 | ||
SK | 07.09.2016 | ||
BG | 07.12.2016 | ||
NO | 07.12.2016 | ||
GR | 08.12.2016 | ||
IS | 07.01.2017 | ||
PT | 09.01.2017 | ||
Former [2017/32] | AT | 07.09.2016 | |
BE | 07.09.2016 | ||
CZ | 07.09.2016 | ||
EE | 07.09.2016 | ||
ES | 07.09.2016 | ||
FI | 07.09.2016 | ||
HR | 07.09.2016 | ||
IT | 07.09.2016 | ||
LT | 07.09.2016 | ||
LV | 07.09.2016 | ||
NL | 07.09.2016 | ||
PL | 07.09.2016 | ||
RO | 07.09.2016 | ||
SE | 07.09.2016 | ||
SK | 07.09.2016 | ||
BG | 07.12.2016 | ||
NO | 07.12.2016 | ||
GR | 08.12.2016 | ||
IS | 07.01.2017 | ||
PT | 09.01.2017 | ||
Former [2017/13] | ES | 07.09.2016 | |
FI | 07.09.2016 | ||
HR | 07.09.2016 | ||
LT | 07.09.2016 | ||
LV | 07.09.2016 | ||
NL | 07.09.2016 | ||
SE | 07.09.2016 | ||
NO | 07.12.2016 | ||
GR | 08.12.2016 | ||
Former [2017/11] | ES | 07.09.2016 | |
FI | 07.09.2016 | ||
HR | 07.09.2016 | ||
LT | 07.09.2016 | ||
SE | 07.09.2016 | ||
NO | 07.12.2016 | ||
GR | 08.12.2016 | ||
Former [2017/10] | FI | 07.09.2016 | |
HR | 07.09.2016 | ||
LT | 07.09.2016 | ||
SE | 07.09.2016 | ||
NO | 07.12.2016 | ||
Former [2017/09] | FI | 07.09.2016 | |
LT | 07.09.2016 | ||
NO | 07.12.2016 | ||
Former [2017/07] | LT | 07.09.2016 | Cited in | International search | [Y]US2007202045 (DENNIS MARK S [US]) [Y] 1-19 * abstract *; | [Y]WO0180899 (CANGENE CORP [CA], et al) [Y] 7,9,12 * page 10, lines 2-5; examples 3,11 *; | [Y]US7211395 (SATO AARON K [US], et al) [Y] 20,21 * column 17, line 63 - column 22, line 67 *; | [YP]WO2009000099 (ESBATECH AG [CH], et al) [YP] 1-19 * the whole document * | [XY] - VITA CLAUDIO, "Engineering novel proteins by transfer of active sites to natural scaffolds", CURRENT OPINION IN BIOTECHNOLOGY, (1997), vol. 8, no. 4, ISSN 0958-1669, pages 429 - 434, XP002551084 [X] 1,4,5 * abstract * [Y] 2,3,6-21 DOI: http://dx.doi.org/10.1016/S0958-1669(97)80064-X | [Y] - CARTER P J, "POTENT ANTIBODY THERAPEUTICS BY DESIGN", NATURE REVIEWS. IMMUNOLOGY, NATURE PUBLISHING GROUP, GB, (20060407), vol. 6, ISSN 1474-1733, pages 343 - 357, XP007901440 [Y] 1-19 * Page 1, section "Pharmacokinetics" * DOI: http://dx.doi.org/10.1038/nri1837 | [YD] - MUMMERT M E ET AL, "DEVELOPMENT OF A PEPTIDE INHIBITOR OF HYALURONAN-MEDIATED LEUKOCYTE TRAFFICKING", JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, JP, (20000918), vol. 192, no. 6, ISSN 0022-1007, pages 769 - 779, XP009081295 [YD] 7,9,12,20,21 * abstract * DOI: http://dx.doi.org/10.1084/jem.192.6.769 | [YD] - SHAUNAK SUNIL ET AL, "Site-specific PEGylation of native disulfide bonds in therapeutic proteins", NATURE CHEMICAL BIOLOGY JUN 2006,, (20060601), vol. 2, no. 6, pages 312 - 313, XP002544349 [YD] 13-15 * the whole document * DOI: http://dx.doi.org/10.1038/nchembio786 | [A] - ZANETTI M ET AL, "EXPRESSION OF CONFORMATIONALLY CONSTRAINED ADHESION PEPTIDE IN AN ANTIBODY CDR LOOP AND INHIBITION OF NATURAL KILLER CELL CYTOTOXIC ACTIVITY BY AN ANTIBODY ANTIGENIZED WITH THE RGD MOTIF", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, (19930101), vol. 12, no. 11, ISSN 0261-4189, pages 4375 - 4384, XP001194410 [A] 1-6,8-19 * abstract * |